Creon (pancrelipase delayed-release) / AbbVie, Eisai  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Creon (pancrelipase delayed-release) / AbbVie, Eisai
NCT02733848: CREON for the Treatment of Post-RYGB Hypoglycemia

Terminated
1
5
NA
Creon, Diet, Placebo
East Carolina University
Hypoglycemia
01/18
01/18
CREON, NCT05266963: Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

Completed
1
11
US
CREON, Placebo
Vanderbilt University Medical Center
Type 1 Diabetes
03/24
03/24
NCT07314489: A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis

Recruiting
1
80
RoW
Creon(Pancreatin Enteric-coated Capsules)
Shanghai Changzheng Hospital
Chronic Pancreatitis Pancreatic Exocrine Insufficiency Blood Glucose
12/26
12/35
ChiCTR2400086621: Study on the efficacy and safety of pancreatic enzyme replacement therapy for total enteral nutrition-related diarrhea in moderately to severely active Crohn's disease

Recruiting
1
100
 
The dosage of Creon (trypsin enteric-coated capsule) (according to the drug instruction manual): 1 tablet every time, once every 2 hours, 6 times a day, and then stop taking it for 4 weeks; Treat according to routine procedure. The control group did not receive trypsin replacement therapy
Department of Gastroenterology, Renmin Hospital of WuhanUniversity; Renmin Hospital of WuhanUniversity, self-finance
Crohn’s disease
 
 

Download Options